Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

EXECUTIVE DIAGNOSTICS LLC

NPI: 1134699945 · JACKSON, MS 39206 · Clinical Medical Laboratory · NPI assigned 12/05/2018

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official SINGH, KIRNJOT controls 20+ related entities in our dataset. Read more

$0.00
Total Medicaid Paid
274
Total Claims
208
Beneficiaries
6
Codes Billed
2022-03
First Month
2022-12
Last Month

Provider Details

Authorized OfficialSINGH, KIRNJOT (PRESIDENT)
NPI Enumeration Date12/05/2018

Related Entities

Other providers sharing the same authorized official: SINGH, KIRNJOT

ProviderCityStateTotal Paid
ELITE DIAGNOSTICS LLC CROWN POINT IN $9.61M
BOA VIDA HOSPITAL OF ABERDEEN, MS, LLC ABERDEEN MS $5.02M
ELITE DIAGNOSTICS, LLC CROWN POINT IN $1.09M
BOA VIDA HOSPITAL OF ABERDEEN, MS, LLC ABERDEEN MS $936K
IMG ASSOCIATES LLC MERRILLVILLE IN $698K
HASKELL REGIONAL HOSPITAL, INC. STIGLER OK $640K
BOA VIDA HOSPITAL OF ABERDEEN, MS LLC NEW HOULKA MS $596K
BOA VIDA HOSPITAL OF ABERDEEN, MS, LLC ABERDEEN MS $590K
BOA VIDA HOSPITAL OF ABERDEEN, MS LLC COLUMBUS MS $567K
HASKELL REGIONAL HOSPITAL, INC. STIGLER OK $510K
HASKELL REGIONAL HOSPITAL, INC. HOLDENVILLE OK $500K
HASKELL REGIONAL HOSPITAL, INC. ADA OK $408K
HASKELL REGIONAL HOSPITAL, INC. WILBURTON OK $398K
HASKELL REGIONAL HOSPITAL, INC STIGLER OK $366K
BOA VIDA HOSPITAL OF ABERDEEN, MS LLC CALHOUN CITY MS $274K
HASKELL REGIONAL HOSPITAL, INC. HEAVENER OK $223K
BOA VIDA HOSPITAL OF ABERDEEN, MS LLC TUPELO MS $180K
BOA VIDA HOSPITAL OF ABERDEEN, MS, LLC NETTLETON MS $164K
BOA VIDA HOSPITAL OF ABERDEEN, MS, LLC AMORY MS $163K
BOA VIDA HOSPITAL OF ABERDEEN, MS, LLC ABERDEEN MS $156K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2022 274 $0.00

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
82542 66 49 $0.00
83516 66 49 $0.00
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 66 49 $0.00
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 52 37 $0.00
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 12 12 $0.00
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 12 12 $0.00